One-day systemic corticosteroid administration for asthma and future "short bursts" risk in real clinical practice.

Autor:	Matsumoto T; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Kaneko A; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Fujiki T; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Kusakabe Y; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Nakayama E; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Tanaka A; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Yamamoto N; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Tashima M; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Ito C; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Aihara K; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Yamaoka S; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan., Mishima M; Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan.
Jazyk:	angličtina
Zdroj:	The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2023 Nov; Vol. 60 (11), pp. 1951-1959. Date of Electronic Publication: 2023 Apr 23.
DOI:	10.1080/02770903.2023.2200854
Abstrakt:	Objective: Systemic corticosteroid administration, also called short bursts (SB), is harmful for patients with asthma; however, the actual burden of one-day SB remains unsolved. This study aimed to elucidate the characteristics of patients requiring one-day SB against asthma in clinical practice. Methods: Consecutive patients who regularly visited our hospital for asthma treatment between January 2019 and December 2020 were reviewed and followed for one year. SB was defined as ≥3 days of systemic corticosteroid treatment for an exacerbation. One-day SB was defined as one-day of systemic corticosteroid to treat an exacerbation. The one-day SB group included patients who received only one-day SB but no SB during the preceding year. Frequent SB was defined as that occurring ≥2 times/year. Results: Data on 229 patients were analyzed. Among them, 2.6% (95% confidence interval 1.2-5.6%) were in the one-day SB group. The one-day SB group was female-dominant, obese, non-eosinophilic, and non-atopic. The median one-day SB was 1.5 times/year and almost half of one-day SB were performed by patients themselves. Independent of the low pulmonary function, high blood eosinophil count, and inhaled corticosteroid dose, one-day SB was associated with future frequent SB (adjusted odds ratio = 18.2, 95% confidence interval 1.1-288, P  = 0.040, compared to the no SB group). Conclusions: Although one-day SB was not frequently experienced, even one-day SB without conventional SB was associated with future frequent SB. It is important to grasp the actual condition of one-day SB and to reinforce the treatment used.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu